Bulletin of Experimental Biology and Medicine

, Volume 162, Issue 4, pp 583–588 | Cite as

Antiproliferative Activity of a New Nitrosyl Iron Complex with Cysteamine in Human Tumor Cells In Vitro

  • O. S. Zhukova
  • Z. S. Smirnova
  • I. O. Chikileva
  • M. V. Kiselevskii
Translated from Kletochnye Tekhnologii v Biologii i Meditsine (Cell Technologies in Biology and Medicine)

We studied cytotoxic activity of a new NO-releasing tetranitrosyl binuclear iron complex with cysteamine (CysAm) for human tumor cells, the relationship between the expression of O6-methylguanine-DNA methyltransferase (MGMT) and cell sensitivity to CysAm, and apoptosis-inducing capacity of this preparation. It was found that histogenetically different cell lines are characterized by different sensitivity to CysAm, and this parameter correlated with the basal level of MGMT. CysAm induced apoptosis via activation of caspases 3 and 7. These data suggest that CysAm can be considered as a potential antitumor agent, but definitive conclusions can be made after preclinical trials.

Key Words

NO-generating nitosyl iron complex human tumor cells cytotoxic activity O6-methylguanine-DNA methyltransferase (MGMT) apoptosis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Zhukova OS. In vitro models in screening of different nature antitumor compounds. Ros. Bioter. Zh. 2004;3(3):12-18. Russian.Google Scholar
  2. 2.
    Lukashin VP, Grebenyuk AN. Comparative analysis of antiradiation effectiveness of different doses of cystamin, heparin, and naphtizin in experiments on mice. Radiats. Biol. Radioekol. 2001;41(3):310-312. Russian.Google Scholar
  3. 3.
    Treshchalina EM, Zhukova OS, Gerasimova GK, Andronova NV, Garin AM. Methodical recommendations on studying antitumor activity of pharmacological substances. Manual for Preclinical Studies of New Pharmacological Substances. Mironov AN, ed. Moscow, 2012. P. 642-656. Russian.Google Scholar
  4. 4.
    Amundson SA, Myers TG, Scudiero D, Kitada S, Reed JC, Fornace AJ Jr. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res. 2000;60(21):6101-6110.PubMedGoogle Scholar
  5. 5.
    An SH, Kang JH, Kim DH, Lee MS. Vitamin C increases the apoptosis via up-regulation p53 during cisplatin treatment in human colon cancer cells. BMB Rep. 2011;44(3):211-216.CrossRefPubMedGoogle Scholar
  6. 6.
    Harris RE, Beebe-Donk J, Doss H, Burr Doss D. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol. Rep. 2005;13(4):559-583.PubMedGoogle Scholar
  7. 7.
    Isono S, Fujishima M, Azumi T, Hashimoto Y, Komoike Y, Yukawa M, Watatani M. O6-methylguanine-DNA methyltransferase as a prognostic and predictive marker for basal-like breast cancer treated with cyclophosphamide-based chemotherapy. Oncol. Lett. 2014;7(6):1778-1784.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Kielbik M, Klink M, Brzezinska M, Szulc I, Sulowska Z. Nitric oxide donors: spermine/NO and diethylenetriamine/NO induce ovarian cancer cell death and affect STAT3 and AKT signaling proteins. Nitric Oxide. 2013;35:93-109.CrossRefPubMedGoogle Scholar
  9. 9.
    Lee BW, Olin MR, Johnson GL, Griffin RJ. In vitro and in vivo apoptosis detection using membrane permeant fluorescent-labeled inhibitors of caspases. Methods Mol. Biol. 2008;414:109-135.PubMedGoogle Scholar
  10. 10.
    Liu L, Xu-Welliver M, Kanugula S, Pegg AE. Inactivation and degradation of O(6)-alkylguanine-DNA alkyltransferase after reaction with nitric oxide. Cancer Res. 2002;62(11):3037-3043.PubMedGoogle Scholar
  11. 11.
    Pop C, Salvesen GS. Human caspases: activation, specificity, and regulation. J. Biol. Chem. 2009;284(33):21,777-21,781.CrossRefGoogle Scholar
  12. 12.
    Sanina NA, Kozub GI, Emelyanova NS, Kondrateva TA, Korchagin DV, Shilov GV, Ovanesyan NS, Aldoshin SM, Zhukova OS. Synthesis, structure, NO donor activity of iron-sulfur nitrosyl complex with 2-aminophenol-2-yl and its antiproliferative activity against human cancer cells. J. Coord. Chem. 2013;66(20):3602-3618.CrossRefGoogle Scholar
  13. 13.
    Takimoto CH. Anticancer drug development at the US National Cancer Institute. Cancer Chemother. Pharmacol. 2003;52(Suppl. 1):S29-S33.CrossRefPubMedGoogle Scholar
  14. 14.
    Tesei A, Zoli W, Fabbri F, Leonetti C, Rosetti M, Bolla M, Amadori D, Silvestrini R. NCX 4040, an NO-donating acetylsalicylic acid derivative: efficacy and mechanisms of action in cancer cells. Nitric Oxide. 2008;19(2):225-236.CrossRefPubMedGoogle Scholar
  15. 15.
    Yamori T. Panel of human cancer cell lines provides valuable database for drug discovery and bioinformatics. Cancer Chemother. Pharmacol. 2003;52(Suppl. 1):S74-S79.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • O. S. Zhukova
    • 1
  • Z. S. Smirnova
    • 1
  • I. O. Chikileva
    • 1
  • M. V. Kiselevskii
    • 1
  1. 1.Laboratory of Cell Immunity, Laboratory of Experimental Cheotherapy, N. N. Blokhin Cancer Research CenterRussian Ministry of HealthMoscowRussia

Personalised recommendations